Drug trial registration/disclosure rule in China signals more inspections
This article was originally published in SRA
Executive Summary
China has introduced registration and disclosure requirements for drug clinical studies that, while their ostensible purpose is to enhance transparency, may also be a prelude to increased clinical trial site inspections by the country's regulator1,2.